Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07123103
PHASE1

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Sponsor: Exelixis

View on ClinicalTrials.gov

Summary

The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.

Official title: A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2025-08-18

Completion Date

2028-02

Last Updated

2026-02-17

Healthy Volunteers

No

Conditions

Interventions

DRUG

XB371

Intravenous (IV) infusion.

Locations (9)

Exelixis Clinical Site #5

Rogers, Arkansas, United States

Exelixis Clinical Site #9

Los Angeles, California, United States

Exelixis Clinical Site #6

Washington D.C., District of Columbia, United States

Exelixis Clinical Site #4

Orlando, Florida, United States

Exelixis Clinical Site #3

Grand Rapids, Michigan, United States

Exelixis Clinical Site #7

New Brunswick, New Jersey, United States

Exelixis Clinical Site #2

Huntersville, North Carolina, United States

Exelixis Clinical Site #8

Houston, Texas, United States

Exelixis Clinical Site #1

San Antonio, Texas, United States